|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 141 | 2018 | Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients | MONTES DIAZ, Gwendoline; FRAUSSEN, Judith; VAN WIJMEERSCH, Bart; Hupperts, R.; SOMERS, Veerle | Journal Contribution | A1 |
| 62 | 2018 | Walking endurance and perceived symptom severity after a single maximal exercise test in persons with mild disability because of multiple sclerosis. | MOUMDJIAN, Lousin; GERVASONI, Elisa; VAN HALEWYCK, Florian; OP 'T EIJNDE, Bert; WENS, Inez; VAN GEEL, Fanny; VAN WIJMEERSCH, Bart; FEYS, Peter; VAN ASCH, Paul | Journal Contribution | A1 |
| 63 | 2017 | Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study | Costers, Lars; Gielen, Jeroen; Eelen, Piet L.; van Schependom, Jeroen; Laton, Jorne; Van Remoortel, Ann; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Seeldrayers, Pierrette; Haelewyck, Marie-Claire; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Langdon, Dawn; Nagels, Guy | Journal Contribution | A1 |
| 64 | 2017 | Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study. | Costers, Lars; Gielen, Jeroen; Eelen, Piet L.; Van Schependom, Jeroen; Laton, Jorne; Van Remoortel, Ann; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Seeldrayers, Pierrette; Haelewyck, Marie-Claire; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Langdon, Dawn; Nagels, Guy | Journal Contribution | M |
| 5 | 2017 | Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation | VANHEUSDEN, Marjan; BROUX, Bieke; Welten, Suzanne P. M.; PEETERS, Liesbet; Panagioti, Eleni; VAN WIJMEERSCH, Bart; SOMERS, Veerle; STINISSEN, Piet; Arens, Ramon; HELLINGS, Niels | Journal Contribution | A1 |
| 6 | 2017 | Teri-DYNAMIC: Exploring the impact of teriflunomide on immune cell population size, receptor repertoire, and function in patients with RRMS | Wiendl, Heinz; Gross, Catharina C.; Eschborn, Melanie; Weisser, Linda; Posevitz-Fejfar, Anita; Schulte-Mecklenbeck, Andreas; VAN WIJMEERSCH, Bart; Hupperts, Raymond; Brette, Sandrine; Turner, Timothy J.; Bar-Or, Amit; Klotz, Luisa | Journal Contribution | M |
| 7 | 2017 | Cytotoxic CD4+T Cells Drive Multiple Sclerosis Progression | PEETERS, Liesbet; VANHEUSDEN, Marjan; SOMERS, Veerle; VAN WIJMEERSCH, Bart; STINISSEN, Piet; BROUX, Bieke; HELLINGS, Niels | Journal Contribution | A1 |
| 8 | 2017 | Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analyses | Comi, G.; Boster, A.; Alroughani, R.; Berkovich, R.; Izquierdo, G.; Kantor, D.; Laganke, C.; Limmroth, V.; Macdonell, R.; Moreau, T.; Sharrack, B.; Wiendl, H.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Melanson, M.; Freedman, M. S. | Journal Contribution | M |
| 9 | 2016 | Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients | CLAES, Nele; FRAUSSEN, Judith; VANHEUSDEN, Marjan; HELLINGS, Niels; STINISSEN, Piet; VAN WIJMEERSCH, Bart; Hupperts, Raymond; SOMERS, Veerle | Journal Contribution | A1 |
| 10 | 2016 | Upper Limb Rehabilitation in People With Multiple Sclerosis: A Systematic Review | LAMERS, Ilse; MARIS, Anneleen; SEVERIJNS, Deborah; Dielkens, Wouter; Geurts, Sander; VAN WIJMEERSCH, Bart; FEYS, Peter | Journal Contribution | A1 |
| 11 | 2016 | Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I study | Arnold, D. L.; Barnett, M.; Comi, G.; Giovannoni, G.; Pelletier, D.; Rovira, A.; Schippling, S.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Traboulsee, A. | Journal Contribution | M |
| 12 | 2016 | Effects of teriflunomide treatment on the CD4(+) T-cell receptor repertoire in patients with relapsing-remitting MS | Klotz, Luisa; Lindner, Maren; Gross, Catherina C.; Eschborn, Melanie; Posevitz-Fejfar, Anita; Schulte-Mecklenbeck, Andreas; Meuth, S. G.; VAN WIJMEERSCH, Bart; Hupperts, Raymond; Maeurer, M.; Stangel, M.; Lang, M.; Tackenberg, B.; Lysandropoulos, A.; Decoo, D.; Eveslage, M.; Turner, Timothy J.; Jagerschmidt, A.; Bar-Or, Amit; Wiendl, Heinz | Journal Contribution | M |
| 13 | 2016 | Brain atrophy by automated MRI reading in long-term natalizumab treated patients: Real world data suggests brain atrophy rates in range of healthy individuals | Horakova, Dana; Uher, T.; Vaneckova, M.; Krasensky, J.; Seidl, Z.; van Pesch, V.; Lysandropoulos, A.; VAN WIJMEERSCH, Bart; Ribbens, A.; van Hecke, W.; Dong, Q.; Farkas, M.; Hyde, R.; Koendgen, H. | Journal Contribution | M |
| 14 | 2016 | Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up) | Oreja-Guevara, C.; Alroughani, R.; Brassat, D.; Boyko, A. N.; McCombe, P.; Steingo, B.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Vermersch, P. | Journal Contribution | M |
| 55 | 2016 | Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I). | Coles, A. J.; Boyko, A. N.; Cohen, J. A.; De Seze, J.; Fox, E. J.; Havrdova, E.; Hartung, H. -P.; Inshasi, J. S.; McCombe, P.; Selmaj, K. W.; Vermersch, P.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Montalban, X. | Journal Contribution | M |
| 56 | 2016 | Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment | Bermel, R.; Comi, G.; Eralinna, J. -P.; Leist, T. P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Bernasconi, C.; Buffels, R.; Csoboth, C.; Han, J.; Musch, B.; Vermersch, P. | Journal Contribution | M |
| 57 | 2016 | B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses | FRAUSSEN, Judith; CLAES, Nele; VAN WIJMEERSCH, Bart; VAN HORSSEN, Jack; STINISSEN, Piet; Hupperts, Raymond; SOMERS, Veerle | Journal Contribution | A1 |
| 58 | 2016 | Effects of an individual 12 weeks community located running program on physical capacity, walking, cognitive function, dual tasking and brain volumes and structures in persons with Multiple Sclerosis. | FEYS, Peter; MOUMDJIAN, Lousin; Vanhalewyck, F.; WENS, Inez; OP 'T EIJNDE, Bert; VAN WIJMEERSCH, Bart; POPESCU, Veronica; Dufour, A.; Delva, S.; VAN ASCH, Paul | Journal Contribution | M |
| 59 | 2015 | Optimizing therapy early in multiple sclerosis: An evidence-based view | Ziemssen, Tjalf; De Stefano, Nicola; Sormani, Maria Pia; VAN WIJMEERSCH, Bart; Wiendl, Heinz; Kieseier, Bernd C. | Journal Contribution | A1 |
| 60 | 2015 | B cells from MS patients induce autoreactive Th1 and Th17 responses | FRAUSSEN, Judith; CLAES, Nele; HELLINGS, Niels; VAN WIJMEERSCH, Bart; STINISSEN, Piet; Hupperts, R.; SOMERS, Veerle | Journal Contribution | M |
Loading...
5
0
5
0
false